# Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

> **NCT00881751** · PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 95 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00881751
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2016-05
- **Final completion:** 2017-02
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2017-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881751, "Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00881751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*